Retina penetration of subconjunctival ranibizumab injection in the rabbit eye

Chinese Journal of Ophthalmology

Volumn 51, Issue 5, 2015, Pages 356-359

  Zhao, Yue'e ^a   Lei, Wensheng ^a  

^a LISHUI CENTRAL HOSPITAL   (China)

Author keywords

Antibodies, monoclonal, humanized; Conjunctiva; Drug administration routes; Intravitreal injections; Osmosis; Retina

Indexed keywords

ANGIOGENESIS INHIBITOR; RANIBIZUMAB;

ANIMAL; AQUEOUS HUMOR; CONJUNCTIVA; ENZYME LINKED IMMUNOSORBENT ASSAY; INTRAVITREAL DRUG ADMINISTRATION; METABOLISM; RABBIT; RANDOMIZATION; RETINA; VITREOUS BODY;

ANGIOGENESIS INHIBITORS; ANIMALS; AQUEOUS HUMOR; CONJUNCTIVA; ENZYME-LINKED IMMUNOSORBENT ASSAY; INTRAVITREAL INJECTIONS; RABBITS; RANDOM ALLOCATION; RANIBIZUMAB; RETINA; VITREOUS BODY;

EID: 84937557480     PISSN: 04124081     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0412-4081.2015.05.010     Document Type: Article

References (15)

1. Haller JA. Current anti-vascular endothelial growth factor dosing regimens: benefits and burden[J]. Ophthalmology, 2013, 120(5 Suppl): s3-7.
2. Puliafito CA. Recalcitrant neovascular macular degeneration after anti-VEGF therapy: an ongoing challenge[J]. Ophthalmic Surg Lasers Imaging Retina, 2013, 44(2): 109.
3. Wells JA, Murthy R, Chibber R, et al. Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation[J]. Br J Ophthalmol, 1996, 80(4): 363-366.
4. Robbie SJ, Lundh von Leithner P, Ju M, et al. Assessing a novel depot delivery strategy for noninvasive administration of VEGF/PDGF RTK inhibitors for ocular neovascular disease[J]. Invest Ophthalmol Vis Sci, 2013, 54(2): 1490-1500.
5. Muniraju R, Ramu J, Sivaprasad S. Three-year visual outcome and injection frequency of intravitreal ranibizumab therapy forneovascular age-related macular degeneration[J]. Ophthalmologica, 2013, 230(1): 27-33.
6. Mendrinos E, Mangioris G, Papadopoulou DN, et al. Long-term results of the effect of intravitreal ranibizumab on the retinal arteriolar diameter in patients with neovascular age-related macular degeneration[J]. Acta Ophthalmol, 2013, 91(3): e184-190.
7. Li J, Zhang H, Sun P, et al. Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients[J]. Int J Ophthalmol, 2013, 6(2): 169-173.
8. Diago T, McCannel CA, Bakri SJ, et al. Infectious endophthalmitis after intravitreal injection of antiangiogenic agents[J]. Retina, 2009, 29(5): 601-605.
9. Ambati J, Canakis CS, Miller JW, et al. Diffusion of high molecular weight compounds through sclera[J]. Invest Ophthalmol Vis Sci, 2000, 41(5): 1181-1185.
10. Boubriak OA, Urban JP, Akhtar S, et al. The effect of hydration and matrix composition on solute diffusion in rabbit sclera[J]. Exp Eye Res, 2000, 71(5): 503-514.
11. Olsen TW, Edelhauser HF, Lim JI, et al. Human scleral permeability: effects of age, cryotherapy, transscleral diode laser, and surgical thinning[J]. Invest Ophthalmol Vis Sci, 1995, 36(9): 1893-1903.
12. Sawada T, Kakinoki M, Wang X, et al. Bimonthly injections of ranibizumab for age-related macular degeneration[J]. Graefes Arch Clin Exp Ophthalmol, 2014, 252(10): 1545-1551.
13. Nomoto H, Shiraga F, Kuno N, et al. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits[J]. Invest Ophthalmol Vis Sci, 2009, 50(10): 4807-4813.
14. Koevary SB. Pharmacokinetics of topical ocular drug delivery: potential uses for the treatment of diseases of the posterior segment and beyond[J]. Curr Drug Metab, 2003, 4(3): 213-222.
15. Xu L, Lu T, Tuomi L, et al. Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a populationapproach[J]. Invest Ophthalmol Vis Sci, 2013, 54(3): 1616-1624.